Document is current
Any future updates will be listed below
-
Authors
Torrente, Daniel
Su, Enming J.
Citalán-Madrid, Alí Francisco
Schielke, Gerald P.
Magaoay, Daniel
Warnock, Mark
Stevenson, Tamara
Mann, Kris
Lesept, Flavie
Delétage, Nathalie
Blanc, Manuel
Norris, Erin H.
Vivien, Denis
Lawrence, Daniel A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (NS132411)
American Parkinson Disease Association
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 6 January 2025
First Online: 14 January 2025
Declarations
:
: All animal procedures were approved by and carried out in accordance with the guidelines of the Institutional Animal Care and Use Committee at the University of Michigan.
: Not applicable.
: Denis Vivien is a co-inventor of the patent TIE13193 (PCT#WO2014187879) concerning glunomab antibody use in neurological disorders and is President of the SAB of Lys Therapeutics. Flavie Lesept and, Nathalie Delétage are employed by Lys Therapeutics, Manuel Blanc is the Chief Executive Officer of Lys Therapeutics which is developing derivatives of Glunomab for pharmaceutical use. The remaining authors declare no competing interests.
